AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis Ruchika Sharma31 Oct 2024 1:45 PM ISTCambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult...
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis Dr. Kamal Kant Kohli20 Sept 2024 9:45 AM ISTAstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with...
AstraZeneca Fasenra approved in China for severe eosinophilic asthma Ruchika Sharma23 Aug 2024 4:05 PM ISTCambridge: AstraZeneca's Fasenra (benralizumab) has been approved in China by the country's National Medical Products Association (NMPA) for the...
FDA approves Benralizumab as Add-On Maintenance Therapy for kids aged 6 to 11 with severe asthma Dr. Kamal Kant Kohli15 April 2024 6:45 AM ISTAstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with...
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
AstraZeneca Asthma drug Fasenra fails one main goal in study of chronic immune disease Ruchika Sharma28 Oct 2022 1:30 PM ISTUK: High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary...
No USFDA approval for AstraZeneca's treatment for chronic nasal condition MD Bureau15 March 2022 3:02 PM ISTThe London-listed drugmaker said the U.S. Food and Drug Administration (FDA) had issued a complete response letter following AstraZeneca's application...
AstraZeneca secures DCGI approval for Benralizumab solution to treat asthma Ruchika Sharma22 Dec 2020 2:16 PM ISTBenralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
